Swedish Orphan Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SWEDISH ORPHAN
SWEDISH ORPHAN has two approved drugs.
There is one US patent protecting SWEDISH ORPHAN drugs.
There are twenty-one patent family members on SWEDISH ORPHAN drugs in twenty-two countries and three supplementary protection certificates in three countries.
Summary for Swedish Orphan
| International Patents: | 21 |
| US Patents: | 1 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Swedish Orphan
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Swedish Orphan | ORFADIN | nitisinone | CAPSULE;ORAL | 021232-001 | Jan 18, 2002 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Swedish Orphan | ORFADIN | nitisinone | CAPSULE;ORAL | 021232-004 | Jun 13, 2016 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Swedish Orphan | ORFADIN | nitisinone | CAPSULE;ORAL | 021232-003 | Jan 18, 2002 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Swedish Orphan | ORFADIN | nitisinone | SUSPENSION;ORAL | 206356-001 | Apr 22, 2016 | RX | Yes | Yes | 9,301,932 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Swedish Orphan
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Swedish Orphan | ORFADIN | nitisinone | CAPSULE;ORAL | 021232-003 | Jan 18, 2002 | 5,550,165 | ⤷ Start Trial |
| Swedish Orphan | ORFADIN | nitisinone | CAPSULE;ORAL | 021232-001 | Jan 18, 2002 | 5,006,158 | ⤷ Start Trial |
| Swedish Orphan | ORFADIN | nitisinone | CAPSULE;ORAL | 021232-002 | Jan 18, 2002 | 5,006,158 | ⤷ Start Trial |
| Swedish Orphan | ORFADIN | nitisinone | CAPSULE;ORAL | 021232-003 | Jan 18, 2002 | 5,006,158 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Swedish Orphan Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 2723320 | ⤷ Start Trial |
| Canada | 2838039 | ⤷ Start Trial |
| Australia | 2012273515 | ⤷ Start Trial |
| Slovenia | 2723320 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Swedish Orphan Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0591275 | SPC/GB05/030 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221 |
| 0591275 | C300198 | Netherlands | ⤷ Start Trial | PRODUCT NAME: NITISINONE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT; REGISTRATION NO/DATE: EU/1/04/303/001-003 20050201 |
| 0591275 | 05C0024 | France | ⤷ Start Trial | PRODUCT NAME: NITISINONE; REGISTRATION NO/DATE: EU/1/04/303/001 20050221 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
